

For Immediate Release

CyGenics and Johns Hopkins University Sign Research Agreement

Key Points:

- Stem cell expansion collaboration with Johns Hopkins University in pre-clinical Acute Myeloid Leukaemia (AML) treatment study.
- The pre-clinical study represents a new treatment strategy for AML patients combining the CyGenics platform and Johns Hopkins technology.
- Completely new application for CyGenics' stem cell expansion platform.
- CyGenics right to exclusively develop and commercialise a combined stem cell purge and expansion kit.

15th November, 2005 – Leading cell therapy company CyGenics Limited (ASX: CYN) announced today that it has entered into a collaborative research agreement with the Johns Hopkins University School of Medicine (Johns Hopkins), a US world leader in research and education in medicine.

The agreement details the use of CyGenics' proprietary stem cell expansion platform in combination with the Johns Hopkins stem cell purging technology, as part of a pre-clinical study directed at a new treatment strategy for patients with Acute Myeloid Leukaemia (AML).

Johns Hopkins has been conducting pre-clinical studies in *ex vivo* expansion of purged stem cell grafts prior to transplant. CyGenics and Johns Hopkins are collaborating to use the CyGenics' proprietary stem cell expansion platform, as the growth platform for these cells. The goal of the collaboration is to include the combined technologies into a clinical study directed at a new treatment strategy for patients with AML.

The current standard treatment for AML is chemotherapy, which often includes several courses, being successful in approximately 65% of patients. When standard chemotherapy is not successful the next option is, high-dose chemotherapy which destroys all bone marrow cells and ongoing blood cell production. Following the high-dose chemotherapy treatment, in order to restore the bone marrow, the patient receives a transplant of autologous (patient's own) stem cells. These stem cells automatically home and start producing new blood cells in the bone marrow.

Patients can suffer a relapse of AML due to the presence of some residual leukaemia in the stem cell graft. A number of studies have shown that treating the stem cell graft to kill off or purge the residual leukaemia prior to transplantation may result in better survival rates for patients undergoing the treatment. However the purging process also kills the original cells that are responsible for the early phases of blood regeneration. This results in delayed engraftment in the patient, during which time the patient is prone to infection and other complications. The goal of the joint program between CyGenics and Johns Hopkins is to evaluate methods for expanding the population of original cells that are responsible for the early phases of rapid stem cell engraftment to enable blood regeneration.



“This is a new and important application for our stem cell expansion platform, as it addresses another current medical need. We are delighted to be able to play a role in these important pre-clinical studies, and look forward to further collaboration with Johns Hopkins in the future.”, said Mr. Ian Brown, Chief Operating Officer of CyGenics.

Mr. Brown added, “This collaboration with Johns Hopkins opens up new opportunities for the commercialisation of our stem cell expansion platform.”

The agreement provides CyGenics with an opportunity to exclusively develop and commercialise a combined stem cell purge and expansion kit aimed at the segment of the market that requires both purging and stem cell expansion.

The US National Cancer Institute expects that in 2005, there will be about 11,960 new cases of AML in the United States alone, and 9,000 deaths. About 5% of childhood leukaemias are AML. Globally, there is an estimated 60,000 new cases annually. In Australia, every year there are about 900 new cases, and in Singapore, approximately 200.

About Johns Hopkins

The mission of the Johns Hopkins School of Medicine is to prepare physicians to practice compassionate clinical medicine of the highest standard and to identify and solve fundamental questions in the mechanisms, prevention and treatment of disease, in health care delivery or in the basic sciences. The aim of the pre-doctoral curriculum of the School of Medicine is to produce leaders in Medicine who will take the foundation of a broad education in Medicine to improve health through patient care, research, and education.

About CyGenics

CyGenics is a cell therapy company focused on the development and commercialization of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

General Inquiries

Steven Fang, CEO, CyGenics Ltd Mob: +61 (0)400 933 243 Email: steven.fang@cygenics.com	Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
--	--

Media Inquiries

Rebecca Piercy, Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au	Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
---	--